Zydus Inks Licensing Agreement With Cms To Develop & Commercialise Desidustat In Greater China

Zydus, A Leading Discovery Based Global Pharmaceutical Company, Has Entered Into A Licensing Agreement With China Medical System Holdings Limited (Cms) For The Development And Commercialisation Of Desidustat, A Novel Oral Hif-Ph Inhibitor For The Treatment Of Anaemia In Patients With Chronic Kidney Disease (Ckd) Not-On-Dialysis And For The Treatment Of Anaemia Ckd Patients On Dialysis In Greater China.It Has Been Reported That More Than 120 Million People Are Estimated To Be Living With Ckd In China. Ckd Is A Serious Medical Condition Which Is An Unmet Healthcare Need Involving Gradual Loss Of Functioning Of Kidneys Eventually Leading To Kidney Failure. If Kidneys Are Healthy They Will Naturally Secrete Beneficial Levels Of A Hormone Called Erythropoietin (Epo), Which Encourages Red Blood Cell Production That Carry Oxygen To The Muscles And Brain. If The Kidneys Are Impaired They Will Produce Reduced Levels Or Tire Of Epo Production Completely, Leading To Fatigue And Anaemia.Anaemia Is One Of The Frequent Complications Of Ckd. A Survey In China Showed That The Prevalence Of Anaemia In Patients At Ckd Stage 1 To 5 Were 22.0%, 37.0%, 45.4%, 85.1%, And 98.2%, Respectively. The Target-Achieving Rate Was Only 8.2% For Anaemia Patients In Non-Dialysis Ckd And 35.2% For Dialysis Ckd, Showing Unmet Healthcare Need.Speaking On The Development, Pankaj R. Patel, Chairman, Zydus Group Said, â‚

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!